Fundraising Fox
/Companies
Sign in

AptamiR Therapeutics

Austin, US · Founded 2012 · Delaware corporation

Find your way into AptamiR Therapeutics

Sign up to see every warm intro you have to AptamiR Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AptamiR Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.

BiotechHealthtechLongevity

Founders & leadership

AptamiR Therapeutics was founded in 2012 by Marc Thibonnier and M. Thibonnier.

MTMarc Thibonnier
Marc ThibonnierCo-founderMarc Thibonnier is a physician-scientist with expertise in internal medicine, endocrinology, nephrology, and clinical pharmacology, holding over 150 peer-reviewed publications. He currently serves as Executive Officer and Director at AptamiR Therapeutics, a biotechnology company developing microRNA-based therapeutics for cardiometabolic and oncology indications.
MT
M. Thibonnier
PC
Philippe CamusExecutive

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2015

▶$3MraisedSep 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Philippe CamusExecutive Officer, Director
  • Marc ThibonnierExecutive Officer, Director
Offering amount
$3M
Amount sold
$3M
Minimum investment
$3M
First sale
Sep 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does AptamiR Therapeutics do?
AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.
Who founded AptamiR Therapeutics?
AptamiR Therapeutics was founded by Marc Thibonnier, M. Thibonnier in 2012.
How much funding has AptamiR Therapeutics raised?
AptamiR Therapeutics has disclosed $3M raised across 1 round.
Where is AptamiR Therapeutics headquartered?
AptamiR Therapeutics is headquartered in Austin, US.